N6-Methyladenosine in Cancer Immunotherapy: an Undervalued Therapeutic Target

Chao Quan,Othmane Belaydi,Jiao Hu,Huihuang Li,Anze Yu,Peihua Liu,Zhenglin Yi,Dongxu Qiu,Wenbiao Ren,Hongzhi Ma,Guanghui Gong,Zhenyu Ou,Minfeng Chen,Yin Sun,Jinbo Chen,Xiongbing Zu

DOI: https://doi.org/10.3389/fimmu.2021.697026

IF: 7.3

2021-01-01

Frontiers in Immunology

Abstract:N 6 -methylation of adenosine (m 6 A), a post-transcriptional regulatory mechanism, is the most abundant nucleotide modification in almost all types of RNAs. The biological function of m 6 A in regulating the expression of oncogenes or tumor suppressor genes has been widely investigated in various cancers. However, recent studies have addressed a new role of m 6 A modification in the anti-tumor immune response. By modulating the fate of targeted RNA, m 6 A affects tumor-associated immune cell activation and infiltration in the tumor microenvironment (TME). In addition, m 6 A-targeting is found to affect the efficacy of classical immunotherapy, which makes m 6 A a potential target for immunotherapy. Although m 6 A modification together with its regulators may play the exact opposite role in different tumor types, targeting m 6 A regulators has been shown to have wide implications in several cancers. In this review, we discussed the link between m 6 A modification and tumor with an emphasis on the importance of m 6 A in anti-tumor immune response and immunotherapy.